← Back to guidelines
Infectious Disease42 papers

Primary adenosquamous carcinoma of cervix

Last edited: 4/10/2026

Overview

Adenosquamous carcinoma of the cervix is a rare subtype of cervical cancer characterized by the presence of both glandular (adenocarcinoma) and squamous cell carcinoma components. It is considered an aggressive form of cervical cancer.

Diagnosis

  • Cervical cancer screening is recommended for all women from age 25 years or at the onset of sexual activity, whichever occurs later, until age 64 years 1.
  • Screening intervals are recommended at 3-year intervals after two consecutive normal annual cytology results, or at 5-year intervals using HPV-based testing 1.
  • Women with HPV-positive, cytology-negative co-test results should undergo repeat co-testing in 12 months or immediate HPV16/18 genotyping 1.
  • A second triage test using cytology, genotyping for HPV16/18, or p16/Ki-67 dual-stain should be conducted for women with positive stand-alone HPV test results to identify those at high risk for high-grade lesions 1.
  • Women with HPV-positive, cytology-positive co-test results, or high-grade abnormal cytology results should be referred for colposcopy 1.
  • Management

  • Treatment with a loop electrosurgical excision procedure is recommended for women with... 1 (Note: The abstract is incomplete regarding specific treatment recommendations for adenosquamous carcinoma).
  • Special Populations

  • Women who have undergone hysterectomy with cervix removal for benign disease and have no prior history of cervical dysplasia can discontinue screening 1.
  • Key Recommendations

  • Primary prevention of cervical cancer is best achieved by vaccinating girls with a prophylactic human papillomavirus (HPV) vaccine 1. (Evidence: Strong)
  • Cervical cancer screening should target all women from age 25 years or at the onset of sexual activity, whichever occurs later, until age 64 years 1. (Evidence: Strong)
  • Screening is recommended at 3-year intervals after two consecutive normal annual cytology results, or at 5-year intervals using HPV-based testing 1. (Evidence: Strong)
  • References

    1 Ngu SF, Cheung ANY, Jong KK, Law JYP, Lee AY, Lee JHS et al.. 2024 Hong Kong College of Obstetricians and Gynaecologists Guidelines for cervical cancer prevention and screening. Hong Kong medical journal = Xianggang yi xue za zhi 2024. link

    Original source

    1. [1]
      2024 Hong Kong College of Obstetricians and Gynaecologists Guidelines for cervical cancer prevention and screening.Ngu SF, Cheung ANY, Jong KK, Law JYP, Lee AY, Lee JHS et al. Hong Kong medical journal = Xianggang yi xue za zhi (2024)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG